Pharma Focus Asia

UK Scientist Develops Simulated Human Heart to Test Drugs\' Effects before Clinical Trials

Aquavit Pharmaceuticals, Inc. has launched a cutting-edge technology the AQUAGOLD® fine touch. It is a first-of-its-kind direct dermal application technology.

Helen Maddock, a scientist from the Centre for Applied Biological and Exercise Sciences at Coventry University, UK, has developed a new technique to safely test a drug's cardiovascular effects without testing initially before they even reach animal or human trials.

The new breakthrough technique called ‘simulated’ cardiovascular system, also known as a work-loop assay, ensures that drugs are tested and determines the negative effects of certain drugs in the early stages.

This realistic heart muscle dynamic modeluses samples of beating heart tissueattached to a rig that allows the muscle to lengthen and shorten while being stimulated by an electrical impulse. And then, scientists can add trial drugs to the tissue and see if there is any negative effect on the contraction of the muscles in the heart.

This confirms drugs are tested before they even reach animal or human trials.

The new technique uses an in vitro method- meaning ‘in glass,’ as it is carried out in a lab environment rather than in a living organism. This is intended to improve the quality of treatment and save hundreds of patients' lives.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Advanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024